Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | PTGES | O14684 | 6/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14732174 | 0.90 | SMN1; SMN2 (0.63) | MAPTPTGESL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL14732084 | 0.89 | L3MBTL1 (0.62) | MAPTPTGESL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL14732159 | 0.79 | SMN1; SMN2 (0.67) | MAPTPTGESLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL14732156 | 0.78 | SMN1; SMN2 (0.63) | MAPTLMNASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL14732106 | 0.73 | SMN1; SMN2 (0.61) | MAPTSMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL19367949 | 0.71 | L3MBTL1 (0.55) | MAPTPTGESL3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL14732175 | 0.69 | KMT2A (0.43) | MAPTPTGESLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4212191 | 0.69 | TSHR (0.67) | MAPTLMNASMN1; SMN2GAAKMT2A | |
| SCHEMBL18559373 | 0.69 | SMN1; SMN2 (1.00) | MAPTSMN1; SMN2ALDH1A1KMT2AHTT | |
| SCHEMBL4212064 | 0.68 | GAA (0.72) | L3MBTL1LMNASMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | ORPHAGEN PHARMACEUTICALS INC (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267712-A1 | MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RORC, RORB, RORA | MAPT 3030/4885PTGES 633/4885L3MBTL1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.